TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10390227

Group type: EXPERIMENTAL
Intervention: Abacavir (600 mg) alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg) alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg) alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Coadministration of Abacavir with Zidovudine and Lamivudine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Coadministration of Zidovudine and Lamivudine with Abacavir
Number of subjects: 15
Study: 9273204

Group type: EXPERIMENTAL
Intervention: AKBR value higher than 0.7 (Group A, 8 subjects)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AKBR between 0.4 and 0.7 (Group B, 2 cases)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AKBR below 0.4 (Group C, 2 cases)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (5 persons)
Number of subjects: 12
Study: 2005227

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (5 mg daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no folic acid supplementation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 8
Study: 6647195

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29733982

Group type: EXPERIMENTAL
Intervention: Parent navigator and a care notebook
Number of subjects: 300

Group type: COMPARATOR
Intervention: Care notebook
Number of subjects: 300
Study: 26713403

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg at baseline and 6 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study: 25918060

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Conventional Medical Treatment Only (MTO)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: BDI screen-positive patients
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Patients with depressive disorder treated with escitalopram
Number of subjects: 1152
Study: 23857024

Group type: EXPERIMENTAL
Intervention: WR 279,396 (15% paromomycin + 0.5% gentamicin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paromomycin Alone (15% paromomycin)
Number of subjects: 30
Study: 19943178

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 18691845

Group type: EXPERIMENTAL
Intervention: Original consent document
Number of subjects: 22

Group type: COMPARATOR
Intervention: Shortened version of consent document
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 15897671

Group type: EXPERIMENTAL
Intervention: Celecoxib (50 + 150 mg, cumulative dose of 200 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 120
Study: 12695239

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10493845

Group type: EXPERIMENTAL
Intervention: Intervention group (n=46)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 151
Study: 8965118

Group type: EXPERIMENTAL
Intervention: Copolymer 1 (Copaxone), daily subcutaneous treatment, dosage not specified, duration not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copolymer 1 (Copaxone)
Number of subjects: 0
Study: 1984496

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 265
Study: 6848810

Group type: EXPERIMENTAL
Intervention: Amiloride-hydrochlorothiazide combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30885666

Group type: EXPERIMENTAL
Intervention: Endometrial injury
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (fertile women)
Number of subjects: 20
Study: 29152910

Group type: EXPERIMENTAL
Intervention: Prosthetic occluding contact lenses (OCLs)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Eye patching
Number of subjects: 2
Study: 25918718

Group type: COMPARATOR
Intervention: Intravenous patient‐controlled analgesia (PCA) with morphine (Group 1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA) with levobupivacaine (Group 2)
Number of subjects: 34
Study: 23710686

Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph (HRT) imaging
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: HRT disc area and pattern standard deviation (PSD)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT)
Number of subjects: 489
Study: 22048172

Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPV-6/11/16/18 vaccine
Number of subjects: 0
Study: 18694603

Group type: EXPERIMENTAL
Intervention: Oral amiodarone (15 mg/Kg then 7 mg/Kg/day for one month)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral bisoprolol (2.5 mg then 2.5 mg bid indefinitely)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral bisoprolol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral amiodarone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 17405996

Group type: EXPERIMENTAL
Intervention: Ovarian ablation or suppression
Number of subjects: 2144

Group type: COMPARATOR
Intervention: No ovarian ablation or suppression
Number of subjects: 2144
Study: 15315305

Group type: EXPERIMENTAL
Intervention: Paclitaxel (90 mg/m2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Docetaxel (45 mg/m2)
Number of subjects: 32
Study: 11159474

Group type: EXPERIMENTAL
Intervention: Ocucoat (hydroxypropyl methylcellulose 2%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Viscoat (sodium chondroitin sulphate 4%-sodium hyaluronate 3%)
Number of subjects: 40
Study: 9757881

Group type: EXPERIMENTAL
Intervention: Systemic methotrexate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic salpingostomy
Number of subjects: 0
Study: 8526970

Group type: EXPERIMENTAL
Intervention: AMPT alone (AMPT/placebo)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: AMPT plus L-dopa/carbidopa
Number of subjects: 41

Group type: COMPARATOR
Intervention: L-dopa/carbidopa alone (placebo plus L-dopa/carbidopa)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo alone (placebo plus placebo)
Number of subjects: 41
Study: 2193407

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diloxanide furoate (study 1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diloxanide furoate (study 2)
Number of subjects: 91
Study: 211316

Group type: EXPERIMENTAL
Intervention: Colestyramine (0.6 g/kg body weight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Colestipol (0.5 g/kg body weight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Colestyramine and Colestipol
Number of subjects: 20
Study: 31029616

Group type: EXPERIMENTAL
Intervention: Bioresorbable everolimus‐eluting scaffold
Number of subjects: 60
Study: 25929529

Group type: EXPERIMENTAL
Intervention: Physical therapy plus general practitioners' care
Number of subjects: 135

Group type: COMPARATOR
Intervention: General practitioners' care alone
Number of subjects: 135
Study: 24196470

Group type: EXPERIMENTAL
Intervention: Dorsal first web-space approach (group D)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Medial transarticular approach (group M)
Number of subjects: 122
Study: 21904959

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Laser ablation
Number of subjects: 21
Study: 19020973

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily plus exemestane 25 mg/day
Number of subjects: 157
Study: 16998765

Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Number of subjects: 27
Study: 15249276

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Paroxetine (in Study II)
Number of subjects: 199
Study: 10930365

Group type: EXPERIMENTAL
Intervention: VSL#3, 6 g/day for 9 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 40
Study: 9369848

Group type: EXPERIMENTAL
Intervention: 45 mg vaginal progesterone every 48 hours
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 90 mg vaginal progesterone every 48 hours
Number of subjects: 31
Study: 1339108

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less aggressive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response to therapy
Number of subjects: 0
Study: 3909841

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified what was administered)
Number of subjects: 60
Study: 30795951

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months during aromatase inhibitor therapy)
Number of subjects: 3425

Group type: COMPARATOR
Intervention: Placebo (matching placebo every 6 months during aromatase inhibitor therapy)
Number of subjects: 3425

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 3425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3425
Study: 29769107

Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention plus email counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pedometer-based intervention alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 0
Study: 26996580

Group type: EXPERIMENTAL
Intervention: Incentive spirometer exercise (ISE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (comprehensive rehabilitation therapy only)
Number of subjects: 50
Study: 25219783

Group type: EXPERIMENTAL
Intervention: OmniGen‐AF(®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 22906338

Group type: EXPERIMENTAL
Intervention: Bupivacaine (20cc of 0.5% bupivacaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (20cc saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 60
Study: 21143094

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 500 (2 g daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Mycophenolate (initial dosage of 0.1 mg/kg/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 17101259

Group type: EXPERIMENTAL
Intervention: LAF group (n = 36) injected with 40 microg of fentanyl and 2% lidocaine hydrochloride with 1:200000 adrenaline
Number of subjects: 71

Group type: COMPARATOR
Intervention: LA group (n = 35) injected with 0.9% saline instead of fentanyl
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: LAF group (n = 36)
Number of subjects: 71

Group type: COMPARATOR
Intervention: LA group (n = 35)
Number of subjects: 71
Study: 15911155

Group type: EXPERIMENTAL
Intervention: Morphine sulfate/dextromethorphan (MS/DM) combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine sulfate (MS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-titrated doses of MS/DM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-titrated doses of MS
Number of subjects: 0
Study: 12142633

Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g) during the ovulatory phase
Number of subjects: 12
Study: 9449270

Group type: EXPERIMENTAL
Intervention: grepafloxacin 400 mg once daily
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg once daily
Number of subjects: 624

Group type: COMPARATOR
Intervention: ciprofloxacin 500 mg twice daily
Number of subjects: 624
Study: 7840070

Group type: EXPERIMENTAL
Intervention: Oat bran-enriched test meal (12.8 g fiber) after 14 days of oat bran feeding (40 g/d)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control diet (15.6 g fiber/d)
Number of subjects: 6
Study: 1969060

Group type: EXPERIMENTAL
Intervention: Intravenous dithiocarb (DTC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral dithiocarb (DTC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DTC (both intravenous and oral)
Number of subjects: 60
Study: 7433475

Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.025%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxymetazoline (formulation in boric acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% Naphazoline
Number of subjects: 0
Study: 31136904

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) applied on the biceps brachii at the contralateral limb
Number of subjects: 40

Group type: COMPARATOR
Intervention: No taping (control)
Number of subjects: 40
Study: 27988093

Group type: EXPERIMENTAL
Intervention: Strengthen your ankle App
Number of subjects: 220

Group type: COMPARATOR
Intervention: Printed Booklet
Number of subjects: 220
Study: 25287366

Group type: COMPARATOR
Intervention: Conventional monovision
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Crossed monovision
Number of subjects: 59
Study: 24084051

Group type: EXPERIMENTAL
Intervention: Dietary magnesium intake
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Meeting the Recommended Dietary Allowance (RDA) for magnesium
Number of subjects: 234
Study: 23560243

Group type: EXPERIMENTAL
Intervention: Buccal smear group (259 subjects)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Blood specimen group (385 subjects)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Pediatric subjects (113 out of 491)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Adult subjects (25 out of 167)
Number of subjects: 644
Study: 19132853

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring system (CGMS) with alarm function activated
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Real-time continuous glucose monitoring system (CGMS) without alarm function activated
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring system (CGMS)
Number of subjects: 1001
Study: 17230105

Group type: EXPERIMENTAL
Intervention: Sural nerve harvesting
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 14
Study: 16083185

Group type: EXPERIMENTAL
Intervention: Chamomile extract (Kamillosan M) spray, 10 puffs of total 370 mg
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no lubrication)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Chamomile extract (Kamillosan M) spray
Number of subjects: 161
Study: 11520381

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale - Telephone version (GDS-T)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale - Personal version (GDS-P)
Number of subjects: 252
Study: 9541761

Group type: EXPERIMENTAL
Intervention: Patients referred by a physician for possible study entry
Number of subjects: 88881

Group type: EXPERIMENTAL
Intervention: Coronary angiographic laboratory record screening
Number of subjects: 88881

Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography (ECG) laboratory patient records
Number of subjects: 88881
Study: 8187120

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3670972

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions of buffy coats from single units of whole blood (0.1 to 0.9 X 10(9) polymorphonuclear leukocytes per kilogram) given daily until ANC > 1,500/microL
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nontransfusion (control group)
Number of subjects: 25
Study: 31834381

Group type: EXPERIMENTAL
Intervention: Maternal smoking heaviness (G0)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maternal non-smoking (G0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal smoking heaviness (G0) on grandchild's (G2) birthweight
Number of subjects: 0
Study: 29679914

Group type: EXPERIMENTAL
Intervention: CAAT‐training (Cannabis Approach‐Avoidance Task Training)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CAAT‐sham training
Number of subjects: 80
Study: 28610969

Group type: EXPERIMENTAL
Intervention: Head-turn gait speed
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Head-forward gait speed
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Balance tolerance limit (BTL)
Number of subjects: 93
Study: 23841567

Group type: EXPERIMENTAL
Intervention: Oral health intervention including individually tailored instructions for oral and/or denture hygiene, relief of dry mouth symptoms, decrease of sugar-use frequency, use of fluoride, xylitol or antimicrobial products, and professional tooth cleaning
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 279
Study: 22798151

Group type: EXPERIMENTAL
Intervention: OTI + PP
Number of subjects: 29

Group type: COMPARATOR
Intervention: CPT
Number of subjects: 29
Study: 20364888

Group type: EXPERIMENTAL
Intervention: Stress session (exposure to a brief standardized psychosocial laboratory stressor)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control session (stress-free)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Stress session
Number of subjects: 29
Study: 18006073

Group type: EXPERIMENTAL
Intervention: Family history of completed suicide
Number of subjects: 4001

Group type: COMPARATOR
Intervention: No family history of completed suicide
Number of subjects: 4001
Study: 15734851

Group type: EXPERIMENTAL
Intervention: Controlled hypoglycemia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Euglycemic clamp
Number of subjects: 24
Study: 12850465

Group type: EXPERIMENTAL
Intervention: Phlebotomy (intervention group [IG], n = 44)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (nonintervention group [NG], n = 47)
Number of subjects: 91
Study: 10097781

Group type: EXPERIMENTAL
Intervention: Experimental case managers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control case managers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Client acuity (measured by ADL functioning and prior hospital use)
Number of subjects: 0
Study: 8866926

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate 200 mg orally (three tablets)
Number of subjects: 6
Study: 1817051

Group type: EXPERIMENTAL
Intervention: herbal extracts
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo preparation
Number of subjects: 50
Study: 7068863

Group type: EXPERIMENTAL
Intervention: Coping skills training group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Counselor intervention group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 30882150

Group type: EXPERIMENTAL
Intervention: CQ+PQ (Chloroquine + Primaquine: 0.25 mg base/kg/day for 14 days)
Number of subjects: 206

Group type: COMPARATOR
Intervention: CQ (Chloroquine: 25 mg base/kg given over 3 days)
Number of subjects: 206
Study: 27746233

Group type: EXPERIMENTAL
Intervention: Inulin (500 mL drink containing 40 g of inulin)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fructose (500 mL drink containing 40 g of fructose)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glucose (500 mL drink containing 40 g of glucose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fructose
Number of subjects: 29

Group type: COMPARATOR
Intervention: Inulin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fructose and inulin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 29
Study: 26554558

Group type: EXPERIMENTAL
Intervention: 300 mg of aspirin once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23928079

Group type: EXPERIMENTAL
Intervention: Pupil size measured by a bedside camera
Number of subjects: 0
Study: 21332626

Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saxagliptin + Glyburide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saxagliptin + Pioglitazone
Number of subjects: 0
Study: 19231103

Group type: EXPERIMENTAL
Intervention: 3D‐PBI (38.5 Gy in 10 fractions)
Number of subjects: 25

Group type: COMPARATOR
Intervention: WBI (50 Gy in 25 fractions)
Number of subjects: 25
Study: 17334259

Group type: COMPARATOR
Intervention: Pressure Support Ventilation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation
Number of subjects: 13
Study: 15468395

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion via pain pump catheter for 48 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (historical patients using oral and intravenous pain medications)
Number of subjects: 16
Study: 12144204

Group type: EXPERIMENTAL
Intervention: Tenderfoot Preemie
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monolet lancet
Number of subjects: 40
Study: 9762795

Group type: EXPERIMENTAL
Intervention: Hypoxaemia (10% O2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hypercapnic hypoxaemia (10% O2 + high CO2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hyperoxaemia (100% O2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperoxaemia (100% O2 + baseline CO2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Renal transplant subjects
Number of subjects: 17
Study: 8086986

Group type: EXPERIMENTAL
Intervention: Presence of e4 allele in patients with Alzheimer's disease
Number of subjects: 980

Group type: COMPARATOR
Intervention: Presence of e4 allele in subjects without dementia
Number of subjects: 980

Group type: COMPARATOR
Intervention: Subjects with no e4 alleles
Number of subjects: 980

Group type: COMPARATOR
Intervention: Subjects with one e4 allele
Number of subjects: 980

Group type: COMPARATOR
Intervention: Subjects with two e4 alleles
Number of subjects: 980